Real-life evaluation of histologic scores for Ulcerative Colitis in remission

被引:9
|
作者
Arkteg, Christian Borde [1 ]
Sorbye, Sveinung Wergeland [2 ]
Riis, Lene Buhl [3 ,4 ]
Dalen, Stig Manfred [2 ]
Florholmen, Jon [1 ,5 ]
Goll, Rasmus [1 ,5 ]
机构
[1] UiT Arctic Univ Norway, Inst Clin Med, Res Grp Gastroenterol Nutr, Tromso, Norway
[2] Univ Hosp North Norway, Dept Clin Pathol, Tromso, Norway
[3] Herlev Gentofte Hosp, Dept Pathol, Herlev, Denmark
[4] Univ Copenhagen, Copenhagen, Denmark
[5] Univ Hosp North Norway, Dept Gastroenterol, Div Internal Med, Tromso, Norway
来源
PLOS ONE | 2021年 / 16卷 / 03期
关键词
RELAPSE; INFLAMMATION; PARAMETERS; PREDICTORS; INFLIXIMAB; AGREEMENT; MARKERS; RISK;
D O I
10.1371/journal.pone.0248224
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Histological evaluation of ulcerative colitis (UC) patients has been debated ever since the first description of the disease and its role in follow-up has never been fully established. Recent evidence suggests an added benefit in accuracy when evaluating if the patient is in remission. Unfortunately, there are several different histological indices, and it is difficult to compare outcomes where different scores are applied. Histopathological evaluation is prone to subjective biases, despite the use of indices. In addition, these indices are developed by expert IBD pathologist, but applied at large, by general pathologist. Therefore, we evaluated the three most applied histological indices for UC on samples from patients in remission to compare test qualities and estimate their usefulness to identify remission by both general and GI specialized pathologist. Method Mucosal biopsies from 41 UC patients in clinical and endoscopic remission were collected as part of a larger study on UC. Three pathologists blinded to the patients' clinical status evaluated them using Geboes score (GS), Nancy Index (NI) and Robarts Histopathological Index (RHI). We calculated the agreement between the pathologists using Inter-class correlation (ICC) and visualized it with ICC-plots and Bland-Altman plots. Association between clinical factors and histological category were analysed by Fisher's exact test. Results The ICC value for GS, RHI and NI were 0.85, 0.73 and 0.70 respectively. The limits of agreement were +/- 6.1, +/- 4.0 and +/- 1.4, for GS, RHI and NI, respectively. Mayo endoscopic subgrade and UC clinical score did not show association with any histological scores. Despite clinical and endoscopic remission 7-35% of the patients displayed histological inflammation on a level classified as active disease, depending on the index and cut-off. Conclusion A substantial amount of UC patients in clinical and endoscopic remission display inflammation on a histological level, but the ability to classify these patients accurately and consistently could be improved.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Efficacy and safety of tofacitinib in the treatment of ulcerative colitis: real-life experience in Andalusia
    Hernandez Martinez, Alvaro
    Navajas Hernandez, Pilar
    Martin Rodriguez, Maria del Mar
    Lazaro Saez, Marta
    Olmedo Martin, Raul
    Nunez Ortiz, Andrea
    Arguelles Arias, Federico
    Fernandez Cano, Maria Carmen
    Gallardo Sanchez, Francisco
    Marin Pedrosa, Sandra
    Gonzalez Garcia, Javier
    Vazquez Moron, Juan Maria
    [J]. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2022, 114 (09) : 516 - 521
  • [22] Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients
    Marisa Iborra
    Natalia García-Morales
    Saoia Rubio
    Federico Bertoletti
    Marta Calvo
    Carlos Taxonera
    Marta Maia Boscá-Watts
    Mónica Sierra
    Noemí Mancenido
    Belén Beltrán
    Óscar Nantes Castillejo
    Esther García-Planella
    Isabel Vera
    Cristina Alba
    David Martí-Aguado
    María Pilar Ballester
    Noelia Cano-Sanz
    Ramón Pajares-Villarroya
    Elena Cerrillo
    Antonio Cañada
    Pilar Nos
    [J]. Scientific Reports, 10
  • [23] Effectiveness of upadacitinib in patients with Ulcerative Colitis: a real-life, multicenter, Italian report
    Teani, I.
    Bevilacqua, N.
    Gabbiadini, R.
    Bezzio, C.
    Ferronato, A.
    Saibeni, S.
    Armuzzi, A.
    Comberlato, M.
    Desideri, F.
    [J]. JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1045 - I1046
  • [24] Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients
    Iborra, Marisa
    Garcia-Morales, Natalia
    Rubio, Saoia
    Bertoletti, Federico
    Calvo, Marta
    Taxonera, Carlos
    Bosca-Watts, Marta Maia
    Sierra, Monica
    Mancenido, Noemi
    Beltran, Belen
    Castillejo, Oscar Nantes
    Garcia-Planella, Esther
    Vera, Isabel
    Alba, Cristina
    Marti-Aguado, David
    Ballester, Maria Pilar
    Cano-Sanz, Noelia
    Pajares-Villarroya, Ramon
    Cerrillo, Elena
    Canada, Antonio
    Nos, Pilar
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [25] Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis
    Detrez, Iris
    Dreesen, Erwin
    Van Stappen, Thomas
    de Vries, Annick
    Brouwers, Els
    Van Assche, Gert
    Vermeire, Severine
    Ferrante, Marc
    Gils, Ann
    [J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 (05): : 575 - 581
  • [26] EFFECTIVENESS OF UPADACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: A REAL-LIFE, MULTICENTER, ITALIAN REPORT
    Teani, I
    Bevilacqua, N.
    Gabbiadini, R.
    Bezzio, C.
    Ferronato, A.
    Saibeni, S.
    Armuzzi, A.
    Comberlato, M.
    Desideri, F.
    [J]. DIGESTIVE AND LIVER DISEASE, 2024, 56 : S244 - S245
  • [27] Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland
    Perrig, Kathrin
    Krupka, Niklas
    Jordi, Sebastian Bruno Ulrich
    Rossel, Jean-Benoit
    Biedermann, Luc
    Greuter, Thomas
    Schreiner, Philipp
    Vavricka, Stephan R.
    Juillerat, Pascal
    Burri, Emanuel
    Zimmermann, Dorothee
    Maillard, Michel H.
    Sulz, Michael Christian
    Brand, Stephan
    Rogler, Gerhard
    Misselwitz, Benjamin
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
  • [28] Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission
    Narula, Neeraj
    Aruljothy, Achuthan
    Alshahrani, Abdul-Aziz
    Fadida, Ma'ayan
    Al-Saedi, Mona
    Marshall, John K.
    Rubin, David T.
    Christensen, Britt
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (11-12) : 1676 - 1682
  • [29] A New Evaluation Method for Remission of Ulcerative Colitis
    Li, Yanan
    Pengbo, Shizhang
    Feng, Yifei
    [J]. GASTROENTEROLOGY, 2023, 164 (07) : 1345 - 1346
  • [30] Considering Histologic Remission in Ulcerative Colitis as a Long-Term Target
    Pavel, Christopher
    Diculescu, Mircea Mihai
    Stepan, Alex-Emilian
    Constantinescu, Gabriel
    Sandru, Vasile
    Tieranu, Cristian George
    Tomescu, Luiza
    Constantinescu, Alexandru
    Patoni, Cristina
    Plotogea, Oana-Mihaela
    Ilie, Madalina
    [J]. JOURNAL OF CLINICAL MEDICINE, 2024, 13 (01)